Using nanoparticles to deliver a new treatment for knee osteoarthritis
Treating knee osteoarthritis by sPLA2 inhibitor-loaded micellar nanoparticles
This study is exploring a new way to help people with knee osteoarthritis by using tiny particles to deliver special medications directly to the painful joint, aiming to improve treatment and possibly slow down the disease instead of just easing the pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10813883 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating knee osteoarthritis (OA) by using micellar nanoparticles to deliver secreted phospholipase A2 (sPLA2) inhibitors directly to the affected joint tissues. The study aims to address the limitations of current anti-inflammatory drugs, which often fail to penetrate the cartilage effectively. By targeting the inflammatory mediators involved in OA progression, this research seeks to develop a more effective treatment option that could potentially modify the disease rather than just alleviate symptoms. Patients may be monitored for changes in pain levels and joint function throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with knee osteoarthritis who experience chronic pain and functional limitations due to the condition.
Not a fit: Patients with knee osteoarthritis who are not responsive to any form of treatment or those with advanced joint degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a disease-modifying treatment for knee osteoarthritis, improving patients' quality of life and potentially reducing the need for joint replacement surgeries.
How similar studies have performed: While the approach of using sPLA2 inhibitors is relatively novel in the context of knee osteoarthritis, similar strategies targeting inflammatory mediators have shown promise in other chronic inflammatory conditions.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cheng, Zhiliang — University of Pennsylvania
- Study coordinator: Cheng, Zhiliang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.